Dr NICHOLAS KINDON Nicholas.Kindon@nottingham.ac.uk
SENIOR RESEARCH FELLOW
Discovery of AZD-2098 and AZD-1678, two potent and bioavailable CCR4 receptor antagonists
Kindon, Nicholas; Andrews, Glen; Baxter, Andrew; Cheshire, David; Hemsley, Paul; Johnson, Timothy; Liu, Yu-Zhen; McGinnity, Dermot; McHale, Mark; Mete, Antonio; Reuberson, James; Roberts, Bryan; Steele, John; Teobald, Barry; Unitt, John; Vaughan, Deborah; Walters, Iain; Stocks, Michael J.
Authors
Glen Andrews
Andrew Baxter
David Cheshire
Paul Hemsley
Timothy Johnson
Yu-Zhen Liu
Dermot McGinnity
Mark McHale
Antonio Mete
James Reuberson
Bryan Roberts
John Steele
Barry Teobald
John Unitt
Deborah Vaughan
Iain Walters
Professor MICHAEL STOCKS MICHAEL.STOCKS@NOTTINGHAM.AC.UK
PROFESSOR OF MEDICINAL CHEMISTRY AND DRUG DISCOVERY
Abstract
N-(5-Bromo-3-methoxypyrazin-2-yl)-5-chlorothiophene-2-sulfonamide 1 was identified as a hit in a CCR4 receptor antagonist high throughput screen (HTS) of a sub-set of the AstraZeneca compound bank. As a hit with a lead-like profile, it was an excellent starting point for a CCR4 receptor antagonist program and enabled the rapid progression through the Lead Identification and Lead Optimization phases resulting in the discovery of two bioavailable CCR4 receptor antagonist candidate drugs.
Citation
Kindon, N., Andrews, G., Baxter, A., Cheshire, D., Hemsley, P., Johnson, T., Liu, Y.-Z., McGinnity, D., McHale, M., Mete, A., Reuberson, J., Roberts, B., Steele, J., Teobald, B., Unitt, J., Vaughan, D., Walters, I., & Stocks, M. J. (in press). Discovery of AZD-2098 and AZD-1678, two potent and bioavailable CCR4 receptor antagonists. ACS Medicinal Chemistry Letters, 8(9), 981–986. https://doi.org/10.1021/acsmedchemlett.7b00315
Journal Article Type | Article |
---|---|
Acceptance Date | Sep 1, 2017 |
Online Publication Date | Sep 1, 2017 |
Deposit Date | Sep 8, 2017 |
Publicly Available Date | Sep 2, 2018 |
Journal | ACS Medicinal Chemistry Letters |
Electronic ISSN | 1948-5875 |
Publisher | American Chemical Society |
Peer Reviewed | Peer Reviewed |
Volume | 8 |
Issue | 9 |
Pages | 981–986 |
DOI | https://doi.org/10.1021/acsmedchemlett.7b00315 |
Keywords | Chemokine receptor 4; MDC; TARC; CCR4; Antagonist |
Public URL | https://nottingham-repository.worktribe.com/output/880038 |
Publisher URL | https://doi.org/10.1021/acsmedchemlett.7b00315 |
Additional Information | This document is the Accepted Manuscript version of a Published Work that appeared in final form in ACS Medicinal Chemistry Letters, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see https://doi.org/10.1021/acsmedchemlett.7b00315 |
Contract Date | Sep 8, 2017 |
Files
ACSMCL_CCR4_final.pdf
(447 Kb)
PDF
You might also like
A novel and selective fluorescent ligand for the study of adenosine A2B receptors
(2024)
Journal Article
Small-Molecule Fluorescent Ligands for the CXCR4 Chemokine Receptor
(2023)
Journal Article
Ligand-directed covalent labelling of a GPCR with a fluorescent tag in live cells
(2020)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search